Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials

Author:

Blondeaux EvaORCID,Xie Wanling,Carmisciano Luca,Mura Silvia,Sanna Valeria,De Laurentiis Michelino,Caputo Roberta,Turletti Anna,Durando Antonio,De Placido Sabino,De Angelis Carmine,Bisagni Giancarlo,Gasparini Elisa,Rimanti Anita,Puglisi FabioORCID,Mansutti Mauro,Landucci Elisabetta,Fabi AlessandraORCID,Arecco LucaORCID,Perachino Marta,Bruzzone MarcoORCID,Boni Luca,Lambertini MatteoORCID,Del Mastro LuciaORCID,Regan Meredith M.

Funder

Ministero della Salute

Associazione Italiana per la Ricerca sul Cancro

Fondazione Italiana per la Ricerca sul Cancro Airc

Publisher

Elsevier BV

Reference31 articles.

1. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?;Gill;Oncologist,2006

2. Research C for DE and. E17 general principles for planning and design of multi-regional clinical trials,2020

3. Evaluation of anticancer medicinal products in man–scientific guideline,2018

4. A randomized trial of five years of letrozole versus placebo after aromatase inhibitor-based therapy: NRG Oncology/NSABP B-42;Mamounas;Lancet Oncol,2019

5. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials;Pagani;J Clin Oncol,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3